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Abstract
Background: The inflammatory response is critical to fight insults, such as pathogen invasion or tissue damage, but
if not resolved often becomes detrimental to the host. A growing body of evidence places non-resolved
inflammation at the core of various pathologies, from cancer to neurodegenerative diseases. It is therefore not
surprising that the immune system has evolved several regulatory mechanisms to achieve maximum protection in
the absence of pathology.
Main body: The production of the anti-inflammatory cytokine interleukin (IL)-10 is one of the most important
mechanisms evolved by many immune cells to counteract damage driven by excessive inflammation. Innate
immune cells of the central nervous system, notably microglia, are no exception and produce IL-10 downstream of
pattern recognition receptors activation. However, whereas the molecular mechanisms regulating IL-10 expression
by innate and acquired immune cells of the periphery have been extensively addressed, our knowledge on the
modulation of IL-10 expression by central nervous cells is much scattered. This review addresses the current
understanding on the molecular mechanisms regulating IL-10 expression by innate immune cells of the brain and
the implications of IL-10 modulation in neurodegenerative disorders.
Conclusion: The regulation of IL-10 production by central nervous cells remains a challenging field. Answering the
many remaining outstanding questions will contribute to the design of targeted approaches aiming at controlling
deleterious inflammation in the brain.
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Background
The process of microglial cells and astrocyte activation is
an essential component of the inflammatory response
against pathogens and damage in the central nervous
system (CNS). However, if not regulated, this process
leads to a series of events that culminate in the damage of
healthy nearby cells. In this context, the tight regulation of
immune cell activation is of utmost importance, to avoid
propagation of neurodegenerative processes. Interleukin
(IL)-10, an anti-inflammatory cytokine, prevents immuno-
pathology in several diseases and disease models, both in
the periphery and in the CNS. Here, we review the current
knowledge on the molecular mechanisms regulating IL-10
production by microglial cells and astrocytes and how that
balances the immune response in the CNS.
Introduction
Interleukin (IL)-10 was identified over two decades ago
[1] and is to date the most studied suppressive molecule
of the immune system. IL-10 plays a critical role in pre-
venting inflammatory and autoimmune pathologies by
limiting the immune response to pathogens and microbial
flora [2]. Mouse models of IL-10 deficiency develop in-
flammatory bowel disease upon colonization of the gut
with particular microorganisms [3], whereas in humans,
genetic studies have confirmed the essential role of IL-10
in preventing deleterious inflammation in the gut [4].
However, the role of IL-10 clearly exceeds the regulation
of intestinal inflammation, as a function for this molecule
has been also described in chronic infection, tumour sur-
veillance and neurodegenerative disorders [5–7].
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IL-10 production was originally ascribed to CD4+ T
helper type 2 (Th2) cells [1]. Since then, IL-10 produc-
tion has been described for a wide variety of immune
cells, including Th1 and regulatory T cells, CD8+ T cells,
B cells, macrophages, dendritic cells, neutrophils and
eosinophils [6]. Notably, some non-haematopoietic cells,
as epithelial cells, are also able to produce IL-10 [8]. The
modulation of IL-10 expression by different cells is com-
plex, with common and cell-specific regulatory molecu-
lar mechanisms in place [6]. These mechanisms include
epigenetic regulation, the expression and activation of
particular transcription factors, the triggering of signal-
ling pathways, and post-transcriptional regulation [6, 9].
It is now evident that deregulation of these fine-tuned
processes is associated with detrimental effects of IL-10.
As such, understanding the regulation of IL-10 expres-
sion by different cells is instrumental for the targeted de-
sign of immune intervention strategies.
IL-10 production in the brain has also been described,
but the cellular sources and regulatory molecular mech-
anisms involved are much less known than those operat-
ing at the periphery. Considering the potential of IL-10
in regulating the immune response in the brain, this lack
of knowledge hampers the development of novel im-
mune modulatory strategies. In this review, we start by
providing a global view on the immune response in the
central nervous system (CNS) and of the potential inter-
est of IL-10 regulation in the context of neuroinflamma-
tion versus neurodegeneration and then discuss our
current understanding on the molecular mechanisms
underlying IL-10 production by CNS cells.
Global concepts on the immune response in the CNS
Although for decades the CNS has been considered an im-
mune privileged site due to the believed absence of a local
immune response, extensive work in the last decade unrav-
elled the presence of a specialized intrinsic innate immune
system in the CNS [10, 11]. Indeed, we now know that im-
mune surveillance actively occurs in the CNS and that its
well-functioning is fundamental to maintain the CNS
homeostasis [10, 11]. Furthermore, classical lymphatic
vessels were recently discovered in the CNS dura mater
[12, 13], establishing a direct interface to the peripheral im-
mune system. Whereas the resident innate immune system
patrols the CNS as a first line of defence, the presence of
the adaptive immune response is controlled by a series of
interfaces that include the brain-blood-barrier and the
choroid plexus that likely represent a protective measure
against immune-mediated damage [14].
The innate immune response is generally classified as
the first line of defence against pathogens, being fast and
relatively non-specific [15, 16]. Innate immune cells ex-
press a wide variety of pattern recognition receptors
(PRRs) which, upon recognition of danger signals,
trigger a series of intracellular cascades that culminate
with the production of immune mediators, among which
pro- and anti-inflammatory cytokines [15]. Collectively,
PRRs recognize pathogen-associated molecular patterns
(PAMPs) present in pathogens and damage-associated
molecular patterns (DAMPs) released by tissue damage
in the absence of infection [16]. Whereas recognition of
PAMPs initiates an immune response aimed at pathogen
clearance, activation of PRRs via DAMPs aims at the
resolution of tissue damage [15]. Recognition of PAMPs
and DAMPs are critical for the organism homeostasis,
and in both cases, the regulation of the initial immune
response is needed, to avoid collateral tissue damage.
Several cells of the CNS, including microglia, astrocytes,
neurons, neural stem cells and endothelial cells express
PRRs [11, 17–20], therefore contributing to the initiation
of the innate immune response. The best-studied cellular
population in this context is by far microglia.
Microglia are the resident macrophages of the brain and
the only CNS cells of haematopoietic origin [21]. Micro-
glia arise from the yolk sac-derived primitive macrophage
population and migrate to the brain early in development,
completing their maturation in the forming CNS [22, 23].
They are thus distinct from other glial cells (i.e. astrocytes
and oligodendrocytes) and neurons, which are derived
from the neuroectoderm [24], and a unique population
among mononuclear phagocytes. Microglia are capable of
self-renewal and do not appear to require replenishment
from circulating bone marrow-originated monocytic pre-
cursors [25]. Nevertheless, in inflammatory conditions
such as in experimental autoimmune encephalitis (EAE),
circulating monocytes are recruited to the CNS, where
they remain functionally distinct from microglia, and par-
ticipate in disease progression [26, 27]. These infiltrating
monocytes only contribute to the CNS myeloid cell pool
in a transient manner [27]. In line with their myeloid ori-
gin, microglia express an array of PRRs and signalling
molecules that allow their response to perturbations in
brain homeostasis, namely with the production of several
cytokines, chemokines and reactive oxygen and nitrogen
species [28, 29]. This response initially provides the envir-
onment needed for neuronal regeneration and functional
recovery, thus being protective in its nature. However, a
deregulated or non-resolving microglial inflammatory re-
sponse may lead to the uncontrolled production of im-
mune mediators and recruitment of peripheral immune
cell populations, which induce secondary damage to intact
tissue and inhibit post-injury CNS repair [27, 30]. Indeed,
deregulated microglial responses have been increasingly
associated with a series of neurodegenerative disorders,
from Alzheimer’s and Parkinson’s diseases to multiple
sclerosis [29, 31, 32]. The classical view of microglia as the
sole innate immune cells of the CNS has been challenged
by findings that place astrocytes as immune players, with
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a critical role in the formation of the glial scar and tissue
integrity restoration [33]. Similarly to microglial cells, as-
trocytes express PRRs, namely surface-expressed toll-like
receptors (TLRs), which upon activation lead to the pro-
duction of several inflammatory mediators [34, 35]. Fi-
nally, neurons, oligodendrocytes and endothelial cells also
express PRRs [35–38] and therefore have the capacity to
contribute to the inflammatory response in the brain.
Neuroprotection vs neurodegeneration: a role for
IL-10 in tipping this balance
The manipulation of the balance between protective and de-
generative neuroinflammation is gaining importance from a
therapeutic point of view. Among the mechanisms in place
to avoid exaggerated neuroimmune responses is the produc-
tion of anti-inflammatory cytokines, such as IL-10. Binding
of IL-10 to its receptor triggers a series of signalling cascades
mediated by the Janus kinase (JAK) signal transducer and ac-
tivator of transcription (STAT) pathway, particularly by
STAT3 [39]. Signalling through the IL-10 receptor regulates
several steps of the immune response, from decreasing cyto-
kine gene expression to down-regulating the expression of
major histocompatibility complex class II (MHC-II) and thus
antigen presentation to T cells [39, 40]. Furthermore, IL-10
has been shown to prevent apoptosis by activating the
phosphatidylinositol-4,5-bisphosphate-3-kinase (PI3K)/Akt
cascade and enhancing the expression of anti-apoptotic fac-
tors as Bcl-2 and Bcl-xl, whilst attenuating that of caspase-3
[40]. The processes mediated by IL-10 (Fig. 1) have import-
ant implications at the CNS level. IL-10 is able to inhibit the
production of pro-inflammatory cytokines by microglia, pro-
tecting astrocytes from excessive inflammation [41, 42]. IL-
10 also acts on astrocytes by potentiating their production of
transforming growth factor (TGF)-β [43]. In neurons, IL-10
receptor signalling has been associated with increased cellu-
lar survival [44, 45] and the regulation of adult neurogenesis
[46, 47]. Thus, IL-10 is an important mediator of the cross-
talk between microglia, astrocytes and neurons. Importantly,
in addition to the evidence placing IL-10 as a regulator of
the immune crosstalk in the CNS, several studies directly
implicate defective IL-10 production or signalling in patients
and animal models of neurological diseases, ranging from
neuropathic pain [48] to multiple sclerosis [49, 50], Alzhei-
mer’s disease [51] or Parkinson’s disease [52].
Microglia continuously survey the surrounding tissue en-
vironment, responding to any disturbance in neuronal
homeostasis [53–55]. Depending on the detected insult and
on the alterations to the microenvironmental niche, a
spectrum of activated microglia results. The two extremes of
this spectrum are M1 and M2 polarized cells, as described
for macrophages of the periphery [56]. Upon detection of tis-
sue injury or infection, or upon activation of microglial
Fig. 1 The role of IL-10 receptor signalling in anti-inflammation. Overview of the IL-10R signalling cascade and the main cellular effects triggered by IL-10
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cultures with lipopolysaccharide (LPS) and interferon (IFN)-
γ, necrotic neurons, oligomers of amyloid-β and α-synuclein,
microglia acquire an activated phenotype, typically referred
to as classical or M1. This phenotype is characterized by the
production of pro-inflammatory mediators, including cyto-
kines, such as tumour necrosis factor (TNF), IL-6 and IL-1β;
chemokines; reactive oxygen species; nitric oxide; and prosta-
glandins [57]. Although important to fight infections or
injury, most of the factors released by M1 microglia are toxic
for neuronal cell cultures. At the other end of the spectrum,
in the presence of IL-4, IL-13 or IL-10, microglia differentiate
into M2 or alternative phenotype, characterized by the
expression of IL-10; heparin-binding lectin (Ym1); cysteine-
rich protein FIZZ-1; and Arginase 1 [57]. The anti-
inflammatory M2 phenotype is neuroprotective and has been
implicated in the resolution of the inflammation, phagocyt-
osis and tissue repair. In recent years, the M1/M2 paradigm
of microglial activation has been increasingly studied in sev-
eral neurodegenerative and neurological diseases, where an
imbalance towards M1 polarization is documented [58, 59].
Therefore, normalizing the imbalance between M1 and M2
microglial polarization states has been proposed as a thera-
peutic target for the treatment of several CNS-linked disor-
ders [60, 61]. In this context, in cell cultures, IL-10 in
combination with IL-13 increased microglial secretion of
activin-A, a neuroprotective TGF-β superfamily member that
promotes oligodendrocyte differentiation [62]. More recently,
in vivo, IL-10 originated from regulatory T cells was shown
to mediate microglia polarization towards the M2 phenotype
ameliorating the outcome of intracerebral haemorrhage [63].
Other approaches to drive M2 microglia include the admin-
istration of anti-inflammatory agents [64], which action may
well be mediated by IL-10, as they are known to enhance IL-
10 expression, as discussed below.
Taking all this together, a variety of methods to increase
IL-10 and test its therapeutic potential in neurological dis-
orders with an immune component have been developed.
These include the administration of recombinant IL-10, the
enhancement of IL-10 production through agonists, the de-
livery of IL-10 through viral vectors or the potentiation of
IL-10-producing T and B regulatory cells [7, 65, 66]. How-
ever, despite the initially high expectations, the therapeutic
success of IL-10 has been conflicting. Taking the case of
multiple sclerosis as an example, the effect of IL-10 admin-
istration during EAE, varies from decreased, to no effect, to
actual increased clinical scores [7, 67]. Several factors may
explain the variability of outcomes upon IL-10-targeted in-
terventions in EAE. Different studies use different routes of
IL-10 administration, thus possibly compromising the bio-
availability of IL-10 in the needed anatomical location. This
is illustrated by the fact that intracranial administration of
IL-10 improved the outcome of EAE [68], whereas systemic
delivery did not [69]. Also, IL-10 appears to be generally
more effective if delivered as gene therapy directly into the
CNS than as recombinant protein [7], which again may re-
flect the bioavailability of the molecule. Finally, data also
suggest that IL-10 enhancement at disease onset, rather
than later on, produced the best effects [66]. It is conceiv-
able that with disease progression both IL-10-producing
and IL-10-responding cells change, and so the action of IL-
10 also varies with time. In a recent study, nasal administra-
tion of a CD3-specific antibody was shown to ameliorate
EAE in an IL-10-dependent manner [65], supporting the
concept that IL-10 activating therapies may also be of inter-
est. The observations reported in the context of EAE find
parallel in other diseases where IL-10 appears as a possible
therapeutic target, as recently reviewed by Kwilasz et al. [7].
To mention a few examples, a role for IL-10 in attenuating
local inflammatory reactions during permanent ischemia
has been described [70]. Also, adenoviral-mediated expres-
sion of human IL-10 in the striatum of mice subjected to
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neu-
rotoxicant model of Parkinson’s disease decreased the
neurodegenerative effect of MPTP administration [71]. Im-
portantly, the benefits of dampening neuroinflammation
are highly dependent on the disease type. In the context of
Alzheimer’s disease, several studies show that skewing in-
nate immunity towards a pro-inflammatory state reduce
amyloid-β deposition in transgenic mouse models, via en-
hancing amyloid-β clearance by microglia [72–78]. In line
with these findings, administration of IL-10 to the brains of
amyloid precursor protein (APP) transgenic mice led to
amyloid-β accumulation accompanied by reduced amyloid-
β phagocytosis by microglia [79]. The detrimental effects of
IL-10 in Alzheimer’s disease were further confirmed as IL-
10 absence in a transgenic mouse model of cerebral amyl-
oidosis resulted in amyloid-β phagocytosis by activated
microglia and in reduced amyloid-β load in the mouse
brains, which ultimately conferred a better outcome of the
disease [80]. Therefore, rebalancing the cerebral innate
immunity by inhibiting actions of key anti-inflammatory
cytokines, such as IL-10, to allow the brain return to a
physiological state may also be a potential therapeutic strat-
egy [80]. Thus, rewiring the immune response, at the
functional, but also temporal and spatial levels, more than
simply blocking inflammation, may prove a better approach
to resolve the neuroimmune element of neurodegeneration.
Therefore, a deep understanding of the cellular and mo-
lecular mechanisms operating to regulate the production of
IL-10 is critical.
Cellular sources of IL-10 in the CNS
Microglial cells are the most investigated innate immune
cells in the brain and thus the main studied cytokine pro-
ducers, including of IL-10. Studies performed in vitro show
that IL-10 production is induced in microglial cells upon
TLR stimulation. Specifically, microglial cells produced IL-
10 upon TLR2, 3, 4 and 9 stimulation [34, 41, 81–84].
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TLR-induced IL-10 production by microglia can be further
regulated by other molecules. This is the case of adenosine
that enhances the production of IL-10 by microglial cells
upon stimulation of TLR2 and 4, whilst down-regulating
the production of pro-inflammatory cytokines [85]. In vitro
activation of purinergic receptors by extracellular ATP, ei-
ther LPS-induced or exogenously provided, induced the
production of IL-10 [86, 87]. Glutamate, the most common
excitatory neurotransmitter, has also been shown to en-
hance the expression of IL-10 by LPS-stimulated microglial
cells [81]. Prostaglandin E2, an immune mediator present in
inflammatory settings, is another example of molecules that
enhance LPS-induced IL-10 expression and secretion [88].
Benfotiamine, a synthetic vitamin B1 derivate, downregu-
lates the production of pro-inflammatory cytokines by
TLR4-stimulated BV2 microglia cell line, whereas up-
regulating that of IL-10 [89]. Mycoepoxydiene was also
shown to potentiate IL-10 production by TLR4-activated
microglial cells, therefore reducing inflammatory markers
[90]. Endocannabinoids enhance IL-10 production by acti-
vated microglia [91], as some anti-inflammatory drugs do
[92]. Cytokines have also been described to impact IL-10
production by microglia. For example, tumour necrosis fac-
tor receptor 2 (TNFR2) triggering upon TLR4-induced
TNF was shown to upregulate IL-10 production, which in
this context was inhibited if in the presence of IFN-γ [93].
This last observation has, however, been contradicted in
another study showing that Th1 cell-derived IFN-γ upregu-
lates IL-10 production by microglial cells [94]. The produc-
tion of IL-10 by microglia can also be induced in a PRR-
independent manner. Glatiramer acetate, an immunomod-
ulatory agent used in relapsing-remitting multiple sclerosis,
was shown to induce secretion of IL-10 by microglial cells
[95]. Resveratrol administration to a microglial cell line pre-
vented hypoxia-induced injury by up-regulating IL-10 and
controlling inflammation [96]. Collectively, these reports
show that the molecules present in the microenvironment
can impact IL-10 production by microglia, thus shaping the
outcome of the inflammatory response. In addition to
microglia, other CNS cells were shown to produce IL-10.
Astrocytes produce IL-10 in response to PAMPs, as
demonstrated in the case of the synthetic TLR3 ligand
(double-stranded RNA) [97], Neisseria meningitidis or
Borrelia burgdorferi [98], HIV membrane proteins [99] or
human herpesvirus 6 if in the presence of IL-1β, TNF or
IFN-γ [100]. Notably, stimulation of the Fcγ receptor I on
the surface of astrocytes also triggers an immune response,
with production of IL-10 [101].
Identification of cellular sources of IL-10 in vivo is more
difficult than in vitro, but many studies report the presence
of IL-10 in the CNS. In vivo TLR4 stimulation upon per-
ipheral or central injection of LPS into wild-type mice,
leads to IL-10 production [52, 102, 103]. IL-10 was also
shown to be elevated in the injured adult brain in several
neurodegenerative diseases and animal models of disease,
such as excitotoxic shock [104], multiple sclerosis [105,
106], EAE [107–109], middle cerebral artery occlusion
[110], traumatic brain injury [111], Alzheimer’s disease
[112] and Parkinson’s disease [113]. Although much is yet
to know concerning IL-10 induction in the injured brain, in
some situations it involved TLR signalling, supporting the
importance of TLRs in inducing IL-10 in the brain. For ex-
ample, IL-10 production during Alzheimer’s disease occurs
through a mechanism involving TLR4 [114]. In line with in
vitro studies, anti-inflammatory drugs induce IL-10 pro-
duction in vivo. In an experimental model of intracerebral
haemorrhage, atorvastatin, a 3-hydroxy-3-methyl-glutaryl-
coenzyme A reductase inhibitor with known anti-
inflammatory properties, upregulated IL-10 in vivo, which
is accompanied by a reduction in the number of activated
microglial cells, and consequently to downregulate that of
TNF [115].
Finally, it is important to refer that much of the im-
mune mediators, including IL-10, present within the
CNS, in the context of disease, are produced by brain-
infiltrating immune cells. Initial activation of microglia
results in the production of several pro-inflammatory
mediators, which favour the brain-blood-barrier
permeabilization and, ultimately, drive the infiltration of
peripheral leukocytes into the CNS, including macro-
phages and T cells. Since macrophages, as microglia, de-
tect PAMPs and DAMPs through the activation of PPRs,
their arrival to the CNS will contribute to the full im-
mune response established, either through the direct
production of cytokines or indirectly through the modu-
lation of the tissue microenvironment faced by microglia
[116]. Likewise, infiltrating T cells may alter the cytokine
milieu and thus reprogram microglia responses into M1
or M2 phenotypes [116]. Therefore, peripheral immune
cells play a relevant role in the outcome of neuroinflam-
mation associated with neurologic disorders.
Molecular mechanisms regulating IL-10
production in the CNS
Gene expression requires the accessibility of tran-
scription factors to DNA, which is achieved through
chromatin remodelling events [117]. DNA methylation,
nucleosome remodelling and covalent histone modifica-
tions, such as acetylation or methylation, are among the
factors that influence the accessibility of chromatin
[118]. Although the epigenetics of the Il10 locus has
been explored in macrophages, dendritic cells and T
cells [6], to date it remains largely unknown in what
concerns the regulation of IL-10 production by CNS
cells. The level of methylation of the Il10 gene was
shown to be an important regulator of Il10 mRNA
transcription in microglial cells in the brains of rats sub-
jected to morphine administration [119].
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Several intracellular signalling cascades are known to
regulate the production of IL-10 by microglia and astro-
cytes (Fig. 2). Among them are the mitogen-activated pro-
tein kinase (MAPKs) extracellular signal-regulated kinase
(ERK) and p38, which signal downstream of PRR activa-
tion and act as positive regulators of IL-10 production in
myeloid cells [6]. ERK activation is also associated with
the induction of IL-10 production by microglial cells upon
TLR4 triggering and in the presence of some IL-10 en-
hancers [90–92, 120]. ERK activation was also reported to
enhance IL-10 production by astrocytes upon TLR3
stimulation [97]. Conflicting reports exist in what con-
cerns the role of p38 activation in IL-10 production by
microglia. Activation of p38 has been shown to induce IL-
10 expression in a microglial cell line upon adenosine
administration [85]. However, in another study, a down-
regulation on the activation of p38 in LPS-stimulated rat
primary cultured microglia has been correlated with an
enhancement in IL-10 prodution [121]. This controversy
may be due to the different models used in both works,
and/or to the distinct stimuli provided to microglial cells
that may activate different molecular pathways. Another
pathway identified as an inducer of IL-10 production by
macrophages and dendritic cells is the tyrosine kinase Syk
[6]. The upregulation of IL-10 upon in vivo adrenalin
injection and transient opening of the blood-brain-barrier,
associated with the upregulation of the FcγRI, involved
the downstream activation of Syk [122]. Finally, the signal-
ling molecules protein kinase R (PKR), c-Jun N-terminal
kinase (JNK) and nuclear factor (NF)-κβ have been identi-
fied as likely players in regulating the Il-10 expression in
TLR3-activated astrocytes [97]. Activation of IL-10 ex-
pression in astrocytes and neurons through HIV mem-
brane proteins was shown to involve the PI3K pathway,
through the activation of the serine/threonine kinase p70
[66, 99]. In all, several pathways have been involved in the
regulation of IL-10 expression by microglia or astrocytes,
illustrating the complexity of the system.
At the transcription factors level (Fig. 2), myocyte en-
hancer factor 2D (MEF2D) has been described to play
an important role in activating IL-10 expression in
microglia. MEF2D is present in microglial cells and in-
creased upon microglia activation through TLR4, then
binding to a MEF2 consensus site in the Il10 promoter
region, stimulating IL-10 transcription [123]. The tran-
scription factor CREB was also shown to induce IL-10
expression downstream of p38 activation [85].
Post-transcriptional control of cytokine production is
critical to ensure that the rapid transcription of cyto-
kines in response to an initial stimulus is also rapidly
turned off so that balanced amounts of pro- and anti-
inflammatory molecules are achieved [124]. This layer of
regulation also operates to control the amount of IL-10
produced, being mostly studied in macrophages and
Fig. 2 Molecular mechanisms regulating IL-10 production in microglia and astrocytes. Signalling cascades, transcription factors and miRNAs involved
in regulating the production of IL-10 in TLR-triggered microglia or astrocytes. Grey arrows indicate positive signals; red lines indicate IL-10 silencing
pathways. Also indicated are known enhancers and blockers of IL-10 production
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dendritic cells, where both the IL-10 mRNA stability
and the expression of specific microRNAs (miRs) are
known to be regulated [9]. As for IL-10-producing CNS
cells (Fig. 2), previous reports demonstrate that the pro-
duction of IL-10 upon TLR4 stimulation is regulated by
miRs. Indeed, the inhibition of miR-466l-3p upon LPS
challenge of microglia is described to lead to an upregu-
lation in the IL-10 production by these cells [125]. In as-
trocytes, the overexpression of another miR, miR-181,
was found to enhance the amount of LPS-induced IL-10
production [126].
Importantly, several mechanisms operate as negative
feedback loops to restrain IL-10 production by CNS cells
(Fig. 2). Activation of the signalling cascade mediated by
glycogen synthase kinase (GSK)-3 functions as an en-
dogenous mechanism to inhibit IL-10 production, whilst
enhancing the production of pro-inflammatory cytokines,
by microglial cells upon TLR4 activation [127]. In line
with this, abrogation of GSK-3, through chemical inhibi-
tors or siRNA, was shown to restore TLR4-induced IL-10
production in microglia with a concomitant reduction in
the levels of pro-inflammatory mediators [82, 128]. Fur-
thermore, blockade of GSK-3 was shown to induce p38
and ERK, thus confirming the role for these MAPKs in
enhancing IL-10 production [82]. A similar role for GSK-3
in regulating IL-10 was previously demonstrated for other
immune cell types [6, 9]. In both microglia and astrocytes,
IL-10 was found to down-regulate its own transcription
and that of the IL-10R when exogenously provided to un-
treated and LPS-treated cells [41].
Conclusions
The importance of the innate immune cells of the CNS to
maintain the brain homeostasis is now fully accepted. In
this context, the instrumental role of microglia for brain
development and functionality is unquestionable [21].
Whether microglia activation is also instrumental for
pathogen elimination, or whether mononuclear cells from
the periphery do this job, remains unclear. In any case, the
immune response triggered in the brain is critical to re-
store homeostasis upon injury. However, above a certain
threshold, the initially immune-protective response may
become immune-degenerative, by causing tissue damage.
Given the demonstrated potential of IL-10 in modulating
brain inflammatory settings, it is of major importance to
understand how IL-10 production is regulated in innate
immune cells of the CNS and how it impacts inflamma-
tory responses in this compartment. Thus, unveiling the
common and the cell-specific mechanisms regulating IL-
10 production in different settings and by different cellular
populations will open new avenues for the development of
specific targets to effectively and efficiently modulate IL-
10. For this, the development of more suitable animal
models, for example cell-specific genetic manipulation of
IL-10, as well as deeper molecular studies of the processes
underlying IL-10 expression and secretion, are required.
Also of utmost importance is the understanding of the
temporal and spatial dynamics of IL-10 production and
action, so that the design of immune interventions may be
optimized. This knowledge will potentiate the use of
immunomodulatory, anti-inflammatory therapies target-
ing IL-10 production in several neurodegenerative condi-
tions where inflammation is harmful.
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